- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 245
matching trials from the live ClinicalTrials.gov search.
- Conditions
- AL Amyloidosis
- Interventions
- Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • New York, New York + 1 more
- Conditions
- Stage IV or Recurrent Non-Small Cell Lung Cancer
- Interventions
- Nivolumab, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 36
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
- Drug
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 16
- States / cities
- Rogers, Arkansas • La Jolla, California • Los Angeles, California + 13 more
- Conditions
- Stroke, Transient Ischemic Attack
- Interventions
- Septal Occluder Device, Antiplatelet Medical Therapy
- Device · Drug
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Interventions
- bempegaldesleukin, sunitinib, nivolumab, cabozantinib
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 20
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more
- Conditions
- Non Squamous Lung Cancer
- Interventions
- treatment
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 84
- States / cities
- Beverly Hills, California • Fontana, California • Loma Linda, California + 53 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 227
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
- Conditions
- Lung Cancer
- Interventions
- Nivolumab, Topotecan, Amrubicin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • New Haven, Connecticut • Atlanta, Georgia + 10 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Tislelizumab, Durvalumab, Ociperlimab, Chemotherapy, Radiotherapy
- Drug · Radiation
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bolivar, Missouri
- Conditions
- Urothelial Cancer
- Interventions
- Erdafitinib, Vinflunine, Docetaxel, Pembrolizumab, Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
- Drug · Device
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Sacramento, California • St. Helena, California + 22 more
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Berkeley, California + 25 more
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 12
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 9 more
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 72
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, ADT, Abiraterone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult T-cell Leukemia-Lymphoma
- Interventions
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
- Biological · Drug
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Breast Cancer
- Interventions
- 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 114
- States / cities
- Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more
- Conditions
- Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 7
- States / cities
- Duarte, California • Orange, California • San Francisco, California + 4 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Carboplatin, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sebastopol, California • Stamford, Connecticut + 23 more
- Conditions
- Multiple Myeloma
- Interventions
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 17
- States / cities
- Duarte, California • Fullerton, California • La Jolla, California + 12 more
- Conditions
- Exotropia
- Interventions
- occlusion treatment
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Months to 10 Years
- Enrollment
- 611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Fullerton, California • Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Investigators choice of SoC, AAA817
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more